cagrilintide semaglutide combination phase 3 2024 Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, 3a study Size and Gauge:30 Gauge, 0.5 mL, 1/2-inch BPC 157 10 MG TPN

cagrilintide semaglutide combination phase 3 2024 Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, 3a study Size and Gauge:30 Gauge, 0.5 mL, 1/2-inch BPC 157 10 MG TPN

BPC 157 10 MG (prefilled syringes) - Nuceria Health, Miami, FL

Each compound retains its individual chemical identity within the formulation

TPN

Size and Gauge:30 Gauge, 0.5 mL, 1/2-inch

Semaglutide activates GLP-1 receptors in the hypothalamic arcuate nucleus and paraventricular nucleus, reducing appetite, slowing gastric emptying, and improving glucose-dependent insulin secretion